Provided by Tiger Fintech (Singapore) Pte. Ltd.

Codexis

2.26
-0.0400-1.74%
Post-market: 2.370.1100+4.87%19:46 EDT
Volume:355.45K
Turnover:796.84K
Market Cap:187.21M
PE:-2.54
High:2.31
Open:2.30
Low:2.21
Close:2.30
Loading ...

Company Profile

Company Name:
Codexis
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
188
Office Location:
200 Penobscot Drive,Redwood City,California,United States
Zip Code:
94063
Fax:
- -
Introduction:
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Directors

Name
Position
John J. Nicols
Director,President and Chief Executive Officer
Bernard J. Kelley
Director
Byron L. Dorgan
Director
David V. Smith
Director
Dennis P. Wolf
Director
Kathleen S. Glaub
Director
Pam P. Cheng
Director
Patrick Y. Yang
Director
Thomas R. Baruch
Director

Shareholders

Name
Position
John J. Nicols
Director,President and Chief Executive Officer
Gordon Sangster
Senior Vice President and Chief Financial Officer
James Lalonde
Senior Vice President, Research & Development
Michael Aldridge
Senior Vice President, Corporate & Strategic Development